JP2019514844A - 抗ｃｄ７３抗体を用いた併用療法 - Google Patents

抗ｃｄ７３抗体を用いた併用療法 Download PDF

Info

Publication number
JP2019514844A
JP2019514844A JP2018546508A JP2018546508A JP2019514844A JP 2019514844 A JP2019514844 A JP 2019514844A JP 2018546508 A JP2018546508 A JP 2018546508A JP 2018546508 A JP2018546508 A JP 2018546508A JP 2019514844 A JP2019514844 A JP 2019514844A
Authority
JP
Japan
Prior art keywords
seq
antibody
cdr2
human
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018546508A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514844A5 (enExample
Inventor
ブライアン・シー・バーンハート
アラン・ジェイ・コーマン
ニルス・ロンバーグ
アーロン・ピー・ヤムニウク
モハン・スリニバサン
カーラ・エイ・ヘニング
ミン・レイ
エマヌエラ・セガ
アンジェラ・グッドイナフ
マリア・ジュア−クンケル
グオドン・チェン
ジョン・エス・サック
リチャード・ワイ・ホアン
マーティン・ジェイ・コーベット
ジョセフ・イー・マイヤーズ・ジュニア
リアン・シュヴァイツァー
サンドラ・ブイ・ハッチャー
レイチェル・アルトゥラ
ハイチュン・ホアン
ピンピン・ジャン
エドワード・ジェイ・ヒルト
マイケル・ネイサン・ヘドリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2019514844A publication Critical patent/JP2019514844A/ja
Publication of JP2019514844A5 publication Critical patent/JP2019514844A5/ja
Priority to JP2022056810A priority Critical patent/JP2022104961A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2018546508A 2016-03-04 2017-03-03 抗ｃｄ７３抗体を用いた併用療法 Pending JP2019514844A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022056810A JP2022104961A (ja) 2016-03-04 2022-03-30 抗ｃｄ７３抗体を用いた併用療法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662303985P 2016-03-04 2016-03-04
US62/303,985 2016-03-04
US201662305378P 2016-03-08 2016-03-08
US62/305,378 2016-03-08
US201662341220P 2016-05-25 2016-05-25
US62/341,220 2016-05-25
US201662363703P 2016-07-18 2016-07-18
US62/363,703 2016-07-18
US201662431987P 2016-12-09 2016-12-09
US62/431,987 2016-12-09
PCT/US2017/020714 WO2017152085A1 (en) 2016-03-04 2017-03-03 Combination therapy with anti-cd73 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022056810A Division JP2022104961A (ja) 2016-03-04 2022-03-30 抗ｃｄ７３抗体を用いた併用療法

Publications (2)

Publication Number Publication Date
JP2019514844A true JP2019514844A (ja) 2019-06-06
JP2019514844A5 JP2019514844A5 (enExample) 2020-04-09

Family

ID=58361103

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018546508A Pending JP2019514844A (ja) 2016-03-04 2017-03-03 抗ｃｄ７３抗体を用いた併用療法
JP2022056810A Pending JP2022104961A (ja) 2016-03-04 2022-03-30 抗ｃｄ７３抗体を用いた併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022056810A Pending JP2022104961A (ja) 2016-03-04 2022-03-30 抗ｃｄ７３抗体を用いた併用療法

Country Status (13)

Country Link
US (1) US20190284293A1 (enExample)
EP (1) EP3423494A1 (enExample)
JP (2) JP2019514844A (enExample)
KR (3) KR20230038311A (enExample)
CN (1) CN109476740A (enExample)
AU (1) AU2017228470A1 (enExample)
BR (1) BR112018067368A2 (enExample)
CA (1) CA3016187A1 (enExample)
EA (1) EA201891983A8 (enExample)
IL (2) IL295230A (enExample)
MX (1) MX2018010473A (enExample)
SG (2) SG10201913033UA (enExample)
WO (1) WO2017152085A1 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023509448A (ja) * 2020-01-03 2023-03-08 インサイト・コーポレイション 抗ｃｄ７３抗体及びその使用
JP2023522365A (ja) * 2020-04-22 2023-05-30 アケソ・バイオファーマ・インコーポレイテッド 抗ｃｄ７３抗体とその利用
JP2023522730A (ja) * 2020-04-22 2023-05-31 アケソ・バイオファーマ・インコーポレイテッド 抗ｃｄ７３／抗ｐｄ－１二重特異性抗体及びその使用
JP2023532234A (ja) * 2020-06-22 2023-07-27 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ｃｄ７３抗体とその用途
JP2023538369A (ja) * 2020-08-17 2023-09-07 アケソ バイオファーマ カンパニー，リミティド 抗ｃｄ７３抗体とその使用
JP2023546743A (ja) * 2020-10-23 2023-11-07 中山康方生物医▲藥▼有限公司 抗ｃｄ７３抗体及びその使用
JP2023554326A (ja) * 2020-12-11 2023-12-27 上海華奥泰生物藥業股▲フン▼有限公司 Ｃｄ７３の抗原結合蛋白及びその使用
JP2024502758A (ja) * 2021-01-13 2024-01-23 上海華奥泰生物藥業股▲フン▼有限公司 Ｃｄ７３結合タンパク質及びその使用

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3789403A1 (en) * 2014-11-11 2021-03-10 MedImmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
BR112017010094A2 (pt) 2014-11-21 2018-02-06 Bristol-Myers Squibb Company anticorpos compreendendo regiões constantes de cadeias pesadas modificadas
EA035766B1 (ru) 2014-11-21 2020-08-07 Бристол-Майерс Сквибб Компани Антитело к cd73 и его применения
NZ792355A (en) 2016-10-11 2025-12-19 Agenus Inc Anti-lag-3 antibodies and methods of use thereof
US20200299400A1 (en) * 2017-05-25 2020-09-24 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
PE20200717A1 (es) 2017-06-22 2020-07-21 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas
AU2018359895A1 (en) * 2017-11-06 2020-05-21 Corvus Pharmaceuticals, Inc. Combination therapy for cancer treatment
WO2019090347A1 (en) * 2017-11-06 2019-05-09 Corvus Pharmaceuticals Inc. Adenosine pathway inhibitors for cancer treatment
WO2019140150A1 (en) * 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
CN118955714A (zh) * 2018-03-09 2024-11-15 凡恩世制药(北京)有限公司 抗cd73抗体及其用途
JP7417530B2 (ja) * 2018-03-09 2024-01-18 アーカス バイオサイエンシズ インコーポレイティド 優先投与される免疫増強薬
KR20200130403A (ko) * 2018-03-09 2020-11-18 아게누스 인코포레이티드 항-cd73 항체 및 그의 사용 방법
JP7565797B2 (ja) * 2018-03-13 2024-10-11 タスク セラピューティクス リミテッド 腫瘍特異的細胞枯渇のための抗ｃｄ２５
JP7611700B2 (ja) 2018-03-27 2025-01-10 ブリストル－マイヤーズ スクイブ カンパニー 紫外線シグナルを使用した力価のリアルタイムモニタリング
BR112020020826A2 (pt) 2018-04-12 2021-01-19 Bristol-Myers Squibb Company Terapia de combinação anticâncer com anticorpo antagonista de cd73 e anticorpo antagonista do eixo pd-1/pd-l1
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
US11161850B2 (en) 2018-07-05 2021-11-02 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
CA3118775A1 (en) 2018-11-12 2020-05-22 Jiangsu Hengrui Medicine Co., Ltd. Anti-cd73 antibody, antigen-binding fragment thereof and application thereof
CN111499747B (zh) * 2019-01-11 2022-03-18 康诺亚生物医药科技（成都）有限公司 一种抗cd73单克隆抗体及其应用
SG11202106963YA (en) 2019-01-11 2021-07-29 Omeros Corp Methods and compositions for treating cancer
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US20220135619A1 (en) 2019-02-24 2022-05-05 Bristol-Myers Squibb Company Methods of isolating a protein
EP3937964A4 (en) 2019-03-12 2022-11-16 Arcus Biosciences, Inc. TREATMENT OF ONCOGENE-DRIVEN CANCERS
CN113874397A (zh) * 2019-03-29 2021-12-31 艾库斯生物科学有限公司 利用鉴定的腺苷指纹治疗癌症
JP2022527334A (ja) * 2019-04-02 2022-06-01 メディミューン，エルエルシー 腫瘍を処置するための抗ｃｄ７３、抗ｐｄ－ｌ１抗体及び化学療法
EP3973274A1 (en) 2019-05-23 2022-03-30 Bristol-Myers Squibb Company Methods of monitoring cell culture media
CN112300279A (zh) * 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
CN115003385A (zh) * 2019-11-15 2022-09-02 建新公司 双互补位cd73抗体
CA3166536A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
WO2021205383A1 (en) * 2020-04-09 2021-10-14 Aprilbio Co., Ltd. Monoclonal antibodies and antigen binding fragments thereof for suppressing cd73 immune checkpoint and uses thereof
WO2021247188A1 (en) 2020-06-05 2021-12-09 Bristol-Myers Squibb Company Cd73 antagonist potency assay and methods of use thereof
CN115803346A (zh) * 2020-07-16 2023-03-14 和铂医药(上海)有限责任公司 Pd-1抗原结合蛋白及其应用
AU2021349415A1 (en) * 2020-09-23 2023-06-01 Medimmune, Llc Treatment methods using anti-cd73 and anti-pd-l1 antibodies and chemotherapy
JP2023544410A (ja) 2020-10-05 2023-10-23 ブリストル－マイヤーズ スクイブ カンパニー タンパク質を濃縮するための方法
JP2024502005A (ja) * 2020-12-29 2024-01-17 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤、ｐｄ－１／ｐｄ－ｌ１阻害剤、及び抗ｃｄ７３抗体を含む併用療法
WO2023143227A1 (zh) * 2022-01-25 2023-08-03 石药集团巨石生物制药有限公司 抗cd73抗体及应用
US12187806B2 (en) 2022-03-04 2025-01-07 Development Center For Biotechnology Anti-CD73 antibodies and use thereof
KR20240156411A (ko) 2022-03-09 2024-10-29 브리스톨-마이어스 스큅 컴퍼니 치료 단백질의 일시적 발현
WO2023230605A1 (en) * 2022-05-26 2023-11-30 I-Mab Biopharma Co., Ltd. A method of treating solid tumor
WO2023227115A1 (en) * 2022-05-26 2023-11-30 I-Mab Biopharma Co., Ltd. A method of treating solid tumor
WO2023227110A1 (en) * 2022-05-26 2023-11-30 I-Mab Biopharma Co., Ltd. Biomarkers and methods for treating nsclc

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015042246A1 (en) * 2013-09-20 2015-03-26 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors

Family Cites Families (199)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0710719T3 (da) 1990-01-12 2007-07-09 Amgen Fremont Inc Frembringelse af xenogene antistoffer
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
EP0702553A1 (en) 1993-12-27 1996-03-27 BAXTER INTERNATIONAL INC. (a Delaware corporation) Water soluble non-immunogenic polyamide cross-linking agents
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
EP0862553A4 (en) 1995-10-03 1999-02-03 Scripps Research Inst CBI ANALOG OF CC-1065 AND THE DUOCARMYCINES
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AU6703198A (en) 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
CA2290485C (en) 1997-05-21 2008-08-05 Biovation Limited Method for the production of non-immunogenic proteins
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
HK1041274B (zh) 1998-12-23 2017-12-01 辉瑞大药厂 抗ctla-4的人单克隆抗体
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CN1763097B (zh) 1999-01-15 2011-04-13 杰南技术公司 具有改变的效应功能的多肽变体
PT1914244E (pt) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
JP4118462B2 (ja) 1999-07-19 2008-07-16 株式会社リコー 携帯電子機器
EP1074563A1 (en) 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
AU784062B2 (en) 1999-08-23 2006-01-19 Dana-Farber Cancer Institute, Inc. Novel B7-4 molecules and uses therefor
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
EP3225632B1 (en) 1999-11-30 2020-05-06 Mayo Foundation for Medical Education and Research Antibodies binding to b7-h1, a novel immunoregulatory molecule
ES2269366T3 (es) 2000-02-11 2007-04-01 Merck Patent Gmbh Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
WO2002060919A2 (en) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
JP2004532038A (ja) 2001-05-17 2004-10-21 ディヴァーサ コーポレイション 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法
NZ529788A (en) 2001-05-31 2003-12-19 Medarex Inc Cytotoxins, prodrugs, linkers and stabilizers useful therefor
BR0213761A (pt) 2001-10-25 2005-04-12 Genentech Inc Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
CA2495251C (en) 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
DE60334141D1 (de) 2002-10-15 2010-10-21 Facet Biotech Corp VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CN1816356A (zh) 2003-05-14 2006-08-09 免疫原公司 药物缀合物组合物
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
CN103394083B (zh) 2003-11-06 2017-07-18 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
US20080089892A1 (en) 2004-01-12 2008-04-17 Eli Lilly And Co. Fc Region Variants
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
US7778814B2 (en) 2004-03-30 2010-08-17 Siemens Aktiengesellschaft Method and device for simulating an automation system
NZ550934A (en) 2004-05-19 2010-05-28 Medarex Inc Chemical linkers and conjugates thereof
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
ES2426816T3 (es) 2004-08-04 2013-10-25 Mentrik Biotech, Llc Regiones Fc variantes
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EA010654B1 (ru) 2004-11-23 2008-10-30 Пи Ай Пи Ко., Лтд. Вмонтированная в стену распределительная коробка водоснабжения
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
US7812135B2 (en) 2005-03-25 2010-10-12 Tolerrx, Inc. GITR-binding antibodies
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
AU2006244885B2 (en) 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
DK2559690T3 (en) 2005-05-10 2016-04-25 Incyte Holdings Corp Modulators of indoleamine 2,3-dioxygenase and methods of use thereof
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
EP1940470B1 (en) 2005-09-26 2013-04-17 Medarex, Inc. Antibody-drug conjugates and their use
WO2007038868A2 (en) 2005-10-03 2007-04-12 The University Of British Columbia Novel enediyne compound and uses thereof
SI1940789T1 (sl) 2005-10-26 2012-03-30 Medarex Inc Postopki in spojine za pripravo cc analogov
US20080206246A1 (en) 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
AR061181A1 (es) 2006-05-25 2008-08-13 Bristol Myers Squibb Co Compuestos de aziridinil-epotilona
PE20080102A1 (es) 2006-05-25 2008-02-11 Bristol Myers Squibb Co Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
JP5319532B2 (ja) 2006-09-19 2013-10-16 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
TW200900059A (en) 2007-02-21 2009-01-01 Medarex Inc Chemical linkers with single amino acids and conjugates thereof
JP2008278814A (ja) 2007-05-11 2008-11-20 Igaku Seibutsugaku Kenkyusho:Kk アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
WO2008147143A2 (en) 2007-05-30 2008-12-04 Postech Academy-Industry Foundation Immunoglobulin fusion proteins
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
DE102007036200A1 (de) 2007-08-02 2009-02-05 Knorr-Bremse Systeme für Nutzfahrzeuge GmbH Induktiver Weg- oder Drehwinkelsensor mit zwischen zwei Spulen angeordnetem Abschirmblech
JP6035009B2 (ja) 2007-08-22 2016-11-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
KR101554753B1 (ko) 2007-10-01 2015-09-22 브리스톨-마이어스 스큅 컴퍼니 메소텔린에 결합하는 인간 항체 및 이의 용도
CN101918027A (zh) 2007-11-02 2010-12-15 森托科尔奥索生物科技公司 半合成GLP-1肽-Fc融合构造、方法及其用途
CA2932121A1 (en) 2007-11-30 2009-06-11 Newlink Genetics Corporation Ido inhibitors
KR20100101124A (ko) 2007-11-30 2010-09-16 브리스톨-마이어스 스큅 컴퍼니 단백질 티로신 키나제 ７ (ｐｔｋ７)에 대한 모노클로날 항체 파트너 분자 컨쥬게이트
AR069747A1 (es) 2007-11-30 2010-02-17 Medarex Inc Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
EP2808345A3 (en) 2007-12-05 2015-03-11 Massachusetts Institute of Technology Aglycosylated immunoglobulin mutants
HUE024903T2 (en) 2007-12-26 2016-02-29 Xencor Inc Fc variants with altered binding to fcrn
FR2927330B1 (fr) 2008-02-07 2010-02-19 Sanofi Aventis Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
AU2009237662A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
CA2975228C (en) 2008-05-02 2020-07-21 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010077643A1 (en) 2008-12-08 2010-07-08 Tegopharm Corporation Masking ligands for reversible inhibition of multivalent compounds
PT2376535T (pt) 2008-12-09 2017-06-23 Hoffmann La Roche Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t
NZ606427A (en) 2009-02-03 2014-10-31 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
US20110007023A1 (en) 2009-07-09 2011-01-13 Sony Ericsson Mobile Communications Ab Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
HUE049825T2 (hu) 2009-09-03 2020-10-28 Merck Sharp & Dohme Anti-GITR antitestek
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
WO2011066389A1 (en) 2009-11-24 2011-06-03 Medimmmune, Limited Targeted binding agents against b7-h1
SI2954779T1 (sl) 2009-12-10 2019-06-28 Regeneron Pharmaceuticals, Inc. Miši, ki proizvajajo težkoverižna protitelesa
MY159679A (en) 2009-12-10 2017-01-13 Hoffmann La Roche Antibodies binding preferentially human csf1r extracellular domain 4 and their use
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
KR101829691B1 (ko) 2010-02-08 2018-02-19 리제너론 파마슈티칼스 인코포레이티드 일반적인 경쇄 마우스
LT2536745T (lt) 2010-02-19 2016-09-26 Xencor, Inc. Nauji ctla4-ig imunoadhezinai
BR112012022210B1 (pt) 2010-03-04 2021-08-17 Macrogenics, Inc Anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado
MX336682B (es) 2010-03-05 2016-01-27 Hoffmann La Roche Anticuerpos contra csf-1r humanos y usos de los mismos.
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
CN102971329B (zh) 2010-04-15 2016-06-29 麦迪穆有限责任公司 用于治疗增殖性疾病的吡咯并苯并二氮杂卓
MX2012011900A (es) 2010-04-15 2013-03-21 Seattle Genetics Inc Conjugados de pirrolobenzodiazepina diana.
KR20200044999A (ko) 2010-05-04 2020-04-29 파이브 프라임 테라퓨틱스, 인크. Ｃｓｆ1ｒ에 결합하는 항체들
KR101970944B1 (ko) 2010-06-22 2019-04-23 리제너론 파아마슈티컬스, 인크. 하이브리드 경쇄 마우스
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
SI2614082T1 (sl) 2010-09-09 2018-12-31 Pfizer Inc. Molekule, ki vežejo 4-1BB
CA2824278C (en) 2010-12-20 2022-09-20 The Rockefeller University Modulating agonistic tnfr antibodies
RU2608504C2 (ru) 2011-02-25 2017-01-18 Чугаи Сейяку Кабусики Кайся FcγRIIb-СПЕЦИФИЧНОЕ Fc-АНТИТЕЛО
EP3144320B9 (en) 2011-04-13 2018-08-22 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
NO2694640T3 (enExample) 2011-04-15 2018-03-17
RS57324B1 (sr) 2011-04-20 2018-08-31 Medimmune Llc Antitela i drugi molekuli koji vezuju b7-h1 i pd-1
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
CA2849039C (en) 2011-09-20 2018-09-18 Spirogen Sarl Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates
WO2013095738A2 (en) 2011-09-27 2013-06-27 Mapp Biopharmaceutical, Inc. Monoclonal antibodies with altered affinities for human fcyri, fcyrllla, and c1q proteins
CN104159921B (zh) 2011-12-15 2018-05-04 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
EP2793943B1 (en) 2011-12-19 2018-09-26 The Rockefeller University Non-sialylated anti-inflammatory polypeptides
CA2861122A1 (en) 2012-02-06 2013-08-15 Genentech, Inc. Compositions and methods for using csf1r inhibitors
EP2814829B1 (en) 2012-02-13 2016-12-07 Bristol-Myers Squibb Company Enediyne compounds, conjugates thereof, and uses and methods therefor
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP3539984A1 (en) 2012-05-11 2019-09-18 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CA3213528A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
TWI713436B (zh) 2012-08-31 2020-12-21 美商戊瑞治療有限公司 用結合群落刺激因子１受體（ｃｓｆ１ｒ）之抗體治療病狀之方法
NZ628446A (en) 2012-09-13 2017-06-30 Bristol Myers Squibb Co Fibronectin based scaffold domain proteins that bind to myostatin
KR102215954B1 (ko) 2013-02-14 2021-02-15 브리스톨-마이어스 스큅 컴퍼니 튜부리신 화합물, 그의 제조 및 사용 방법
KR102536786B1 (ko) * 2014-10-10 2023-05-26 이나뜨 파르마 에스.에이. Ｃｄ７３ 차단
MY191423A (en) 2014-11-10 2022-06-27 Medimmune Ltd Binding molecules specific for cd73 and uses thereof
EP3789403A1 (en) 2014-11-11 2021-03-10 MedImmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
BR112017010094A2 (pt) * 2014-11-21 2018-02-06 Bristol-Myers Squibb Company anticorpos compreendendo regiões constantes de cadeias pesadas modificadas
EA035766B1 (ru) * 2014-11-21 2020-08-07 Бристол-Майерс Сквибб Компани Антитело к cd73 и его применения

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015042246A1 (en) * 2013-09-20 2015-03-26 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLINICAL CANCER RESEARCH, vol. 19, no. 20, JPN6021007518, 2013, pages 5626 - 5635, ISSN: 0004649434 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023509448A (ja) * 2020-01-03 2023-03-08 インサイト・コーポレイション 抗ｃｄ７３抗体及びその使用
JP2023522365A (ja) * 2020-04-22 2023-05-30 アケソ・バイオファーマ・インコーポレイテッド 抗ｃｄ７３抗体とその利用
JP2023522730A (ja) * 2020-04-22 2023-05-31 アケソ・バイオファーマ・インコーポレイテッド 抗ｃｄ７３／抗ｐｄ－１二重特異性抗体及びその使用
JP7763780B2 (ja) 2020-04-22 2025-11-04 中山康方生物医▲藥▼有限公司 抗ｃｄ７３／抗ｐｄ－１二重特異性抗体及びその使用
JP2023532234A (ja) * 2020-06-22 2023-07-27 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ｃｄ７３抗体とその用途
JP2023538369A (ja) * 2020-08-17 2023-09-07 アケソ バイオファーマ カンパニー，リミティド 抗ｃｄ７３抗体とその使用
JP2023546743A (ja) * 2020-10-23 2023-11-07 中山康方生物医▲藥▼有限公司 抗ｃｄ７３抗体及びその使用
JP2023554326A (ja) * 2020-12-11 2023-12-27 上海華奥泰生物藥業股▲フン▼有限公司 Ｃｄ７３の抗原結合蛋白及びその使用
JP2024502758A (ja) * 2021-01-13 2024-01-23 上海華奥泰生物藥業股▲フン▼有限公司 Ｃｄ７３結合タンパク質及びその使用

Also Published As

Publication number Publication date
EA201891983A1 (ru) 2019-02-28
AU2017228470A1 (en) 2018-08-30
KR20220033522A (ko) 2022-03-16
BR112018067368A2 (pt) 2019-01-15
KR20230038311A (ko) 2023-03-17
WO2017152085A8 (en) 2020-04-16
US20190284293A1 (en) 2019-09-19
IL295230A (en) 2022-10-01
EP3423494A1 (en) 2019-01-09
WO2017152085A1 (en) 2017-09-08
MX2018010473A (es) 2018-09-28
SG10201913033UA (en) 2020-03-30
SG11201806861SA (en) 2018-09-27
AU2017228470A8 (en) 2020-04-23
JP2022104961A (ja) 2022-07-12
EA201891983A8 (ru) 2020-05-28
KR20180118725A (ko) 2018-10-31
CN109476740A (zh) 2019-03-15
CA3016187A1 (en) 2017-09-08
IL261395A (en) 2018-10-31

Similar Documents

Publication Publication Date Title
JP7235712B2 (ja) Ｃｄ７３に対する抗体およびその使用
JP7119051B2 (ja) Ｏｘ４０に対する抗体およびその使用
JP2022104961A (ja) 抗ｃｄ７３抗体を用いた併用療法
JP2025128184A (ja) Ｔｉｇｉｔに対する抗体
JP7762186B2 (ja) Ｔｉｍ３に対する抗体およびその使用
JP2019508013A (ja) グルココルチコイド誘発腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
TW201811829A (zh) 針對tim3之抗體及其用途
HK40036870A (en) Antibodies against cd73 and uses thereof
EA040561B1 (ru) Способ применения антитела к ox40 (варианты)
HK1246308B (en) Antibodies against ox40 and uses thereof
HK1244817B (en) Antibodies against cd73 and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210309

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210806

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211130